2 Stocks I’d Stay Far Away From Today

MedMen Enterprises Inc (CNSX:MMEN) has declined by 40% in the past year, and that’s still not enough to make the stock a good buy.

| More on:

We’ve seen some great deals appear on the markets lately amid a lot of selling that’s been taking place. However, some stocks remain unappealing buys today, even if they were to continue falling. Below are two stocks that I couldn’t be convinced to buy anytime soon.

MedMen Enterprises (CNSX:MMEN) looked like a very appealing buy even a year ago. The stock was trading at more than $9 a share back in October and was looking like it could be a real big player in the cannabis industry south of the border. Its Apple-like stores have been able to draw in many customers, and it has proven to be a very popular brand.

Since then, however, we’ve seen a lot of changes both in the industry and in MedMen as well. We’ve seen some big multi-state operators proving to be formidable opponents for MedMen, including the biggest, Curaleaf Holdings. The battle for market share has proven to be intense in the industry, and it shows no signs of slowing down.

Although MedMen has been able to generate more than $100 million in sales over the trailing 12 months, its losses have continued to mount, and the company has been burning through lots of cash along the way. The problem could become worse, as MedMen recently announced it would be offering home delivery in California, which could become another costly venture.

The stock may appear cheap, trading at around four times its sales, but the reality is that the stock is a very risky one that could continue to fall even further. With many key people leaving the organization in the past year and all sorts of problems facing the company, it may even be one of the worst cannabis stocks to buy today.

Restaurant Brands International (TSX:QSR)(NYSE:QSR) is another stock I’d avoid, but not for the same reasons as MedMen. Restaurant Brands is a quality stock, but it’s just not one that I’d consider buying — not anytime soon. It pays a dividend, has some great restaurant chains in its portfolio, and posts a profit. It looks like a great stock from afar, but there are multiple reasons I wouldn’t invest in it.

First and foremost, it’s a very expensive stock to own. At more than 40 times earnings and around 14 times its book value, investors that buy the stock today are paying a significant premium for it. That would be okay if the company were achieving incredible growth, but that hasn’t been the case. Same-store sales growth numbers haven’t been strong at all, especially at Tim Hortons.

Restaurant Brands also has a lot of debt on its books, and that could continue to get worse, especially as it continues to expand its brands across the globe. For investors, it could be a concern, because if the company needs to raise additional cash, it might have to start coming out of new share issues and that would dilute existing shareholders.

The stock could be a good buy under the right circumstances, but it would have to be a lot cheaper, and its debt would have to come down significantly. Otherwise, there’s simply too much risk here for Restaurant Brands to be an appealing buy.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any of the stocks mentioned. David Gardner owns shares of Apple. The Motley Fool owns shares of Apple and RESTAURANT BRANDS INTERNATIONAL INC and has the following options: short October 2019 $82 calls on RESTAURANT BRANDS INTERNATIONAL INC, short January 2020 $155 calls on Apple, long January 2020 $150 calls on Apple, short January 2020 $155 calls on Apple, and long January 2020 $150 calls on Apple.

More on Cannabis Stocks

Medicinal research is conducted on cannabis.
Cannabis Stocks

What to Know About Canadian Cannabis Stocks for 2025

Let's dive into two top Canadian cannabis stocks and where they may be headed from here (given the recent moves…

Read more »

Researcher works in hemp field
Cannabis Stocks

Aurora Cannabis Stock Is up 46% in 2025: Are Investors Going From 5 Years of Pain to a 2025 Gain?

Shares of Aurora Cannabis have staged a comeback in 2025, outpacing the broader markets comfortably. Is ACB stock a good…

Read more »

A plant grows from coins.
Stocks for Beginners

3 Growth Stocks That Could Skyrocket in 2025 and Beyond

It could be a big year for these sectors, and these growth stocks in particular throughout 2025.

Read more »

money goes up and down in balance
Tech Stocks

2 TSX Stocks to Buy and 2 to Avoid in the Looming Trade War

The looming U.S.-Canada trade war has changed the business environment. Here are some TSX stocks to buy and avoid in…

Read more »

space ship model takes off
Cannabis Stocks

2 Canadian Stocks With Strong Momentum for 2025

Celestica Inc. (TSX:CLS) stock and Dollarama (TSX:DOL) stock have sustained strong price growth momentum for a long time.  Here’s why…

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Pot Stocks: Buy, Sell, or Hold in 2025?

Cannabis stocks remain a bit risky, but could long-term investors be in for more pain or far more profits?

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Could the Cannabis Bubble Re-Inflate?

Let's dive into the question of whether the Canadian cannabis bubble can re-inflate from here.

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Should You Buy Canopy Growth Stock or Green Thumb Stock Today?

Let's dive into two cannabis giants, and which one may be the better pick for long-term investors.

Read more »